Samsung Biologics to increase production, develop different drug formats

Samsung Biologics will focus on scaling up its production and research sites for the coming decades with an aim of venturing into new drug formats like vaccines and developing new medication beyond its core biosimilar business.

2021-01-13

New CEO takes the helm at Samsung Biologics

Samsung Biologics’ new chief executive John Rim officially took office on Wednesday, following the approval of the company’s board of directors on the same day. His appointment marks the first change in the company's leadership in its 9-year history.

2020-12-16

New CEOs named to Samsung bio, construction and heavy industries affiliates

Samsung Biologics named Executive Vice President John Rim as the new CEO of the biopharmaceutical affiliate of Samsung on Tuesday, acknowledging his experience at well-known multinational drug makers.

2020-12-08

Samsung Biologics produces Lilly Covid-19 treatment

Samsung Biologics is mass producing Eli Lilly’s antibody treatment for the new coronavirus, the Korean biopharmaceutical company said Tuesday.

2020-11-17

Samsung Biologics lands CDO deal with Chinese biotech firm

Samsung Biologics signed a contract development organization (CDO) deal with GeneQuantum, a Chinese biotech venture, the Korean company said Monday.

2020-11-02

Samsung Biologics opens San Francisco R&D center

Samsung Biologics opened its first overseas research & development (R&D) center in San Francisco on Thursday. The 500-acre research unit is dedicated to the bio-pharmaceutical company’s contract development organization (CDO) business.

2020-10-29

Samsung Biologics reports 27% rise in third-quarter net

Samsung Biologics reported 56.1 billion won ($49.5 million) in net profit for the third quarter, a 27 percent on-year increase.

2020-10-21

LG once led Korea's bio industry — where did it all go wrong?

In the early 2000s, Korea’s largest conglomerates Samsung, LG and SK were all executing massive investment plans in the field of biopharmaceuticals — a highly unfamiliar realm to Koreans at the time.

2020-10-05

Samsung Biologics signs supply deal with AstraZeneca

Samsung Biologics has signed a three-year supply deal worth $330.8 million with British pharmaceutical firm AstraZeneca. Under the contract deal, Samsung Biologics will produce drug substances and products for AstraZeneca through Dec. 2023.

2020-09-22

Samsung Biologics to build fourth factory in Incheon

Samsung Biologics will build its largest factory in Songdo, Incheon, with an investment totaling 1.74 trillion won ($1.47 billion). This will be the company’s fourth plant, all in Incheon's Songdo District.

2020-08-11

Home > >